RxDoctor Payments Data

Hung Manh Nguyen, DO

Family Medicine · Orange, CANPI 1447284526

Payments from drug & device makers

$490in general payments, 2019–2025

Across 16 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$248
  • Stryker$150
  • Exact Sciences$40
  • Bayer$22
  • Philips North America LLC$18
  • Johnson & Johnson$12

What the payments were for

  • Food & beverage$490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$490 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$832,996
Medicare patients
586
Services billed
5,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$121,991
AustedoDeutetrabenazine11$44,222
XareltoRivaroxaban66$40,847
JanuviaSitagliptin Phosphate81$23,763
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl85$23,585
XifaxanRifaximin21$14,933
LinzessLinaclotide22$12,809
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog75$11,845
JardianceEmpagliflozin21$11,049
Midodrine Hcl117$10,071
Atorvastatin Calcium660$8,742
Gabapentin458$8,184
FarxigaDapagliflozin Propanediol13$7,423
Memantine Hcl151$6,864
Levetiracetam165$6,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$12$40,84766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →